These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24107523)

  • 1. [Open innovation for Japanese pharmaceutical companies].
    Hoshino T
    Nihon Yakurigaku Zasshi; 2013 Oct; 142(4):184-9. PubMed ID: 24107523
    [No Abstract]   [Full Text] [Related]  

  • 2. [Open innovation: public-private partnerships in pharmaceutical R&D].
    Uchibayashi N
    Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):32-8. PubMed ID: 23842226
    [No Abstract]   [Full Text] [Related]  

  • 3. [Open innovation and licensing in the pharmaceutical industry].
    Yamasaki M
    Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):28-31. PubMed ID: 23842225
    [No Abstract]   [Full Text] [Related]  

  • 4. Grants4Targets: an open innovation initiative to foster drug discovery collaborations.
    Dorsch H; Jurock AE; Schoepe S; Lessl M; Asadullah K
    Nat Rev Drug Discov; 2015 Jan; 14(1):74-6. PubMed ID: 25430867
    [No Abstract]   [Full Text] [Related]  

  • 5. Open innovation: share or die..
    Talaga P
    Drug Discov Today; 2009 Nov; 14(21-22):1003-5. PubMed ID: 19778629
    [No Abstract]   [Full Text] [Related]  

  • 6. Can open-source drug R&D repower pharmaceutical innovation?
    Munos B
    Clin Pharmacol Ther; 2010 May; 87(5):534-6. PubMed ID: 20407458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Q&A: Bernard Munos.
    Bender E
    Nature; 2016 May; 533(7602):S59. PubMed ID: 27167392
    [No Abstract]   [Full Text] [Related]  

  • 9. Novelty in the target landscape of the pharmaceutical industry.
    Agarwal P; Sanseau P; Cardon LR
    Nat Rev Drug Discov; 2013 Aug; 12(8):575-6. PubMed ID: 23903214
    [No Abstract]   [Full Text] [Related]  

  • 10. To make better therapeutics, companies strive to increase the content of results and get them faster.
    Szpir M
    Biotechniques; 2007 Apr; 42(4 Suppl):S3-5. PubMed ID: 18798735
    [No Abstract]   [Full Text] [Related]  

  • 11. Ask the experts: future of the pharmaceutical industry. Interview by Future Medicinal Chemistry.
    Cottens S; Eaton M; Fuhr J; Geary S; Johnson DS; Li G; Raveglia L; Robertson GM; Westwell A
    Future Med Chem; 2011 Nov; 3(15):1863-72. PubMed ID: 22023030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A lesson from Japan: research and development efficiency is a key element of pharmaceutical industry consolidation process.
    Shimura H; Masuda S; Kimura H
    Drug Discov Ther; 2014 Feb; 8(1):57-63. PubMed ID: 24647159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
    Hedner T; Gatenbeck L
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
    [No Abstract]   [Full Text] [Related]  

  • 14. The current state of drug discovery and what it might take to improve drug discovery outcomes and approval successes.
    Turner MJ
    Drug Discov Today; 2015 Aug; 20(8):917-9. PubMed ID: 26100736
    [No Abstract]   [Full Text] [Related]  

  • 15. [Consideration on Industry-Academia Partnering in Drug Discovery Development: Based on a Questionnaire Survey of Pharmaceutical Companies and Academia].
    Iida K; Yano T; Ikemori M; Ishida T; Nishimura N
    Yakugaku Zasshi; 2021 Jun; 141(6):877-886. PubMed ID: 33642438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Michael Rosenblatt.
    Nat Rev Drug Discov; 2016 Sep; 15(10):672. PubMed ID: 27681789
    [No Abstract]   [Full Text] [Related]  

  • 17. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.
    Spellberg B; Sharma P; Rex JH
    Nat Rev Drug Discov; 2012 Feb; 11(2):168. PubMed ID: 22293569
    [No Abstract]   [Full Text] [Related]  

  • 18. Antibacterial R&D incentives.
    Laxminarayan R; Powers JH
    Nat Rev Drug Discov; 2011 Sep; 10(10):727-8. PubMed ID: 21959280
    [No Abstract]   [Full Text] [Related]  

  • 19. Ian Tomlinson.
    Tomlinson I
    Nat Rev Drug Discov; 2016 Mar; 15(3):154. PubMed ID: 26893183
    [No Abstract]   [Full Text] [Related]  

  • 20. Biopharma deal-making in 2016.
    Micklus A; Muntner S
    Nat Rev Drug Discov; 2017 Mar; 16(3):161-162. PubMed ID: 28209988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.